Matrix Global Advisors (MGA) is an economic policy consulting firm in Washington, DC, specializing in fiscal, health care, and tax policy matters. Drawing on years of policy experience, the MGA team writes white papers and expert reports, and offers strategic advice to our clients.
Our Expertise. Founder and CEO Alex Brill served as the chief economist and policy advisor for the House Committee on Ways and Means from 2002 to 2007. Afterwards, he assembled the small, dedicated team of experts that comprise MGA.
Our Reputation. We are known for our unbiased analysis and strategic advice, as well as our strong ability to communicate to decision-makers. From Congressional testimony to economic studies to mass media, our insights are heard and appreciated.
Our Size. The small size of our firm is a distinguishing strength. Nothing is ever delegated—we directly handle all analysis, writing, and client interactions.
Biosimilars represent a significant cost-savings opportunity in the United States because they can introduce competition for some of the most expensive and widely used prescription drugs on the market: originator biologics. Several market and regulatory barriers have slowed biosimilar market entry and uptake in the United States.
On October 15th, Alex Brill made a special appearance on CNBC’s “Squawk Box” to discuss President Biden’s corporate tax increase and the effects of rising inflation on the U.S. economy.
In his article for Intellectual Asset Management (IAM), Life Sciences Reporter Adam Houldsworth discusses the weaknesses in the US patent system that enable the “thorny” problem of patent thickets. MGA’s report, “How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing,” was featured heavily in the article to provide evidence of the growing problem.
Three policy experts join Richard Rubin of The Wall Street Journal to examine the current iteration of the Build Back Better Act.
The bipartisan infrastructure bill approved by the Senate on August 10 includes a number of budget gimmicks that help make it look fully “paid for.” One of the gimmicks is pension smoothing, which allows private companies to make smaller contributions to their defined-benefit pension plans, thereby endangering the plans’ financial viability over time.
In a new BioWorld article, Mari Serebrov discusses efforts by Congress to control US prescription drug prices. Interviewed for the article was MGA’s Alex Brill, who talks about the potential side effects of such efforts.